.After antibody-drug conjugate (ADC) professional Seagen was marketed to Pfizer in 2013 for a tremen...
.On the heels of a stage 3 win that neglected to excite real estate investors, Ironwood Pharmaceutic...
.Don't quit Monte Rosa Therapies right now. The Boston-based biotech is having a ball after authoriz...
.Welcome to recently's Chutes & Ladders, our roundup of notable management hirings, firings and a...
.Celebrating his provider's upsized initial public offering (IPO), Septerna CEO Jeffrey Finer rang t...
.AbbVie has gone back to the source of its own antipsychotic goliath Vraylar seeking another hit, pa...
.GenSight Biologics is weeks out of losing amount of money. Once more. The biotech merely has suffic...
.Monopar Rehabs is actually recuperating a medicine from the scrap heap of AstraZeneca's uncommon he...
.With brand new data out on Arcus Biosciences' speculative HIF-2a inhibitor, one team of experts fig...
.After developing a gene treatment relationship along with Dyno Therapeutics in 2020, Roche is actua...